Recombinant Bovine Sphingosine 1-phosphate receptor 1 (S1PR1)

What is the structure and function of S1PR1 in bovine tissues?

S1PR1 is a G-protein-coupled receptor expressed predominantly in endothelial cells, T cells, and other cell types. In bovine tissues, it shares high sequence homology with human and mouse variants. The receptor consists of seven transmembrane domains with an extracellular N-terminus and intracellular C-terminus domain. Functionally, S1PR1 primarily couples to Gi proteins and regulates critical cellular processes including cell migration, proliferation, and barrier integrity .

When expressing recombinant bovine S1PR1, it's important to note that the receptor maintains its natural folding only when expressed in eukaryotic systems that allow proper post-translational modifications. Studies have demonstrated that S1PR1 plays crucial roles in regulating endothelial barrier function, immune cell trafficking, and vascular development .

What are the recommended expression systems for producing recombinant bovine S1PR1?

For successful expression of functional recombinant bovine S1PR1, eukaryotic expression systems are strongly preferred over prokaryotic systems. Yeast expression systems, particularly Pichia pastoris, have demonstrated effectiveness in producing properly folded S1PR1 protein that maintains native conformational epitopes . This approach was successfully employed in developing monoclonal antibodies against S1PR1, where properly folded protein was essential for immunization .

For mammalian expression, HEK293 or CHO cell lines typically yield properly folded receptor with appropriate post-translational modifications. When designing expression constructs, consider:

Regardless of the expression system chosen, include appropriate purification tags that won't interfere with receptor functionality, and validate protein folding using functional assays like ligand binding .

How can I verify the functionality of recombinant bovine S1PR1?

Verifying the functionality of recombinant bovine S1PR1 requires multiple complementary approaches. First, establish ligand binding capacity using radiolabeled or fluorescently labeled S1P or synthetic agonists. Competition binding assays can determine affinity constants .

Second, assess Gi protein coupling using GTPγS binding assays or downstream signaling measurements. For instance, S1PR1 activation typically leads to Akt phosphorylation, which can be measured by Western blotting . Additionally, S1PR1 functionality can be verified through receptor internalization assays using confocal microscopy - properly functioning S1PR1 should internalize upon stimulation with S1P or FTY720-P .

A recommended validation protocol includes:

• Binding assays with S1P or synthetic ligands

• Measurement of downstream signaling (Akt phosphorylation)

• Receptor internalization assays using imaging techniques

• Functional readouts specific to endothelial cells, such as barrier integrity or migration assays

How does S1PR1 interact with other G-protein coupled receptors in cardiovascular research models?

S1PR1 exhibits significant cross-talk with other GPCRs in cardiovascular systems, most notably with β1-adrenergic receptors (β1AR). Research has revealed a direct and GRK2-dependent interaction between β1AR and S1PR1 that has profound physiological implications for cardiac function . This interaction appears bidirectional, with reciprocal downregulation occurring between these receptors that impacts cardiac hypertrophy, apoptosis, and remodeling processes .

In experimental cardiovascular models, researchers have observed that:

• Chronic heart failure leads to upregulation of G-protein-coupled receptor kinase 2 (GRK2), which contributes to β-adrenergic receptor downregulation and desensitization

• This β-adrenergic receptor dysregulation corresponds with loss of inotropic reserve in failing myocardium

• S1PR1 downregulation worsens left ventricular dysfunction in established myocardial damage models

These interactions suggest that when designing experiments with recombinant bovine S1PR1, researchers should consider potential cross-talk with β1AR, especially in cardiovascular research contexts. Experimental designs should include controls that account for this interaction, such as selective blocking of either receptor to isolate specific signaling pathways .

What role does recombinant S1PR1 play in studying endothelial barrier function and vascular leak?

Recombinant S1PR1 has become instrumental in deciphering the molecular mechanisms underlying endothelial barrier integrity and vascular leak. Studies utilizing S1PR1 overexpression and knockout models have demonstrated that endothelial S1PR1 signaling protects against pathological retinal vascular leak and angiogenesis . Specifically, S1PR1 activation in endothelial cells restrains the development of pathological angiogenesis by reducing VEGF-induced neovascular tufts in oxygen-induced retinopathy models .

When using recombinant bovine S1PR1 to study barrier function:

• Compare Gi-biased agonists (like SAR247799) versus full agonists to distinguish pathway-specific effects

• Monitor changes in tight junction proteins (ZO-1, claudins) and adherens junction proteins (VE-cadherin)

• Implement transendothelial electrical resistance (TEER) measurements for real-time barrier function analysis

• Conduct in vitro permeability assays using fluorescently-labeled dextrans of various molecular weights

Recent structural studies of the S1PR1-Gi signaling complex at 3.47 Å resolution revealed the recognition mode for biased ligands, offering mechanistic insights into how specific S1PR1 activation patterns can selectively enhance endothelial barrier function without affecting immune cell egress . This has profound implications for developing targeted therapies for endothelial dysfunction-associated diseases .

How can recombinant S1PR1 be utilized in studying the immunomodulatory effects in tumor microenvironments?

Recombinant S1PR1 serves as a valuable tool for investigating the complex immunomodulatory functions within tumor microenvironments. Research has revealed that S1PR1 signaling in T cells drives regulatory T cell (Treg) accumulation in tumors, limits CD8+ T cell recruitment and activation, and ultimately promotes tumor growth . These findings highlight the potential of S1PR1 as a target for cancer immunotherapy.

When designing experiments to study immunomodulatory effects:

• Expression system considerations: The recombinant protein should maintain native conformation to accurately mimic physiological interactions. Mammalian expression systems are preferred for immunological studies.

• Genetic manipulation approaches: Studies using T cell-specific S1PR1-deficient mice (S1pr1^-/-^) showed dramatic reduction of Tregs in tumors, while T cell S1PR1-transgenic mice (S1pr1-Tg) exhibited enhanced Treg accumulation in tumors . This bidirectional manipulation reveals S1PR1's critical role in T cell trafficking to tumors.

• Treg quantification protocols: When assessing Treg populations, analyze:

• Flow cytometry panel design: Include markers for Tregs (CD4+, Foxp3+, CD25+) alongside S1PR1 expression analysis to correlate receptor levels with functional phenotypes .

These approaches provide mechanistic insights into how S1PR1 regulates immune cell trafficking and function within the tumor microenvironment, offering potential therapeutic strategies targeting this pathway.

What are the optimal detection methods for recombinant bovine S1PR1 in different experimental systems?

Detection of recombinant bovine S1PR1 requires tailored approaches depending on the experimental context. For antibody-based detection, monoclonal antibodies specifically recognizing S1PR1 are recommended for their consistency and specificity. The development of monoclonal antibody clone 2B9, which recognizes an epitope on the intracellular domain of S1PR1, represents a significant advancement in detection tools .

For Western blotting applications, sample preparation is critical. Membrane proteins like S1PR1 require appropriate detergent-based extraction (typically 1% Triton X-100 or NP-40), careful temperature control (avoid boiling, which can cause aggregation), and inclusion of phosphatase inhibitors to preserve phosphorylation states .

Immunofluorescence detection benefits from fixation optimization:

For flow cytometry detection, careful optimization of staining protocols is essential. When using commercial antibodies against human or mouse S1PR1, cross-reactivity with bovine S1PR1 should be validated. Surface versus total S1PR1 staining protocols should be developed to distinguish receptor localization .

How should receptor internalization assays be designed to study S1PR1 trafficking?

Receptor internalization assays are crucial for studying S1PR1 dynamics and signaling regulation. When designing these assays for recombinant bovine S1PR1, several methodological considerations are important.

For live-cell imaging approaches:

• Express fluorescently-tagged S1PR1 (C-terminal tags are preferred to avoid interference with ligand binding)

• Establish baseline membrane localization before stimulation

• Add S1P (physiological ligand) or FTY720-P (functional antagonist causing internalization) at appropriate concentrations (typically 100nM-1μM)

• Image at defined intervals (0, 5, 15, 30, 60 minutes) to capture internalization kinetics

• Include appropriate controls (vehicle, receptor mutants deficient in internalization)

Alternative quantitative approaches include flow cytometry-based internalization assays, which can provide population-level data on receptor trafficking. In these assays, surface S1PR1 is labeled before and after stimulation, allowing measurement of internalization rates across cell populations .

Biochemical fractionation approaches complement imaging studies by separating plasma membrane fractions from endosomal compartments, followed by Western blotting to quantify receptor translocation between compartments. These assays should include markers for plasma membrane (Na+/K+ ATPase) and endosomal compartments (Rab5, EEA1) to verify fractionation quality .

What considerations are important when designing experiments to study S1PR1-mediated transendothelial transport?

Designing robust experiments to study S1PR1-mediated transendothelial transport requires careful methodological planning. S1PR1 activation appears to enhance transendothelial HDL transport through a mechanism involving increased cell surface abundance of SR-BI, similar to the activation of S1P1 by S1P or VEGF receptor 2 by VEGF-A .

When establishing transendothelial transport models:

• Endothelial cell selection: Primary human aortic endothelial cells (HAECs) or bovine aortic endothelial cells (BAECs) grown to confluence on permeable supports create physiologically relevant barriers. Cell passage number should be controlled (typically <P8) to maintain stable phenotypes .

• Transwell setup optimization:

  • Pore size: 0.4-3.0 μm depending on experimental questions

  • Coating: Fibronectin or collagen to promote endothelial attachment

  • TEER measurements: Verify barrier integrity before experiments

  • Permeability controls: Include FITC-dextran to monitor barrier function

• Selective pathway manipulation:

  • Pharmacological approach: Compare selective S1PR1 and S1PR3 agonists/antagonists

  • Genetic approach: Use siRNA knockdown of S1PR1 and related receptors

  • Control for off-target effects: Include scrambled siRNA controls

• Lipoprotein preparation:

  • Use fluorescently-labeled HDL (typically DiI or Alexa Fluor labeled)

  • Include size exclusion chromatography to ensure homogeneity

  • Verify functional capacity through cholesterol efflux assays

When interpreting results, consider that S1PR1 and S1PR3 may have overlapping functions in transport regulation. Interference with SR-BI abrogates enhanced binding, uptake, and transport of HDL elicited by S1P receptor agonists, suggesting mechanistic convergence on this pathway .

What are the common pitfalls in S1PR1 expression studies and how can they be addressed?

Researchers frequently encounter several challenges when working with recombinant bovine S1PR1. These pitfalls and their solutions include:

• Low expression levels: S1PR1, like many GPCRs, often expresses poorly in heterologous systems. To address this:

  • Use codon-optimized sequences for the expression host

  • Include molecular chaperones like GRP78/BiP as co-expression partners

  • Consider fusion partners that enhance expression (e.g., BRIL, T4 lysozyme) while maintaining function

  • Implement inducible expression systems with careful optimization of induction conditions

• Receptor misfolding: Improper folding leads to non-functional receptors that may aggregate in expression systems:

  • Reduce expression temperature (28-30°C instead of 37°C for mammalian cells)

  • Add chemical chaperones to media (e.g., 4-phenylbutyrate, DMSO at low concentrations)

  • Validate folding using conformation-sensitive approaches like binding of conformation-specific antibodies

• Antibody cross-reactivity: Many commercial antibodies show poor specificity:

  • Validate antibody specificity using S1PR1 knockout/knockdown controls

  • Use multiple antibodies targeting different epitopes

  • Consider epitope-tagged constructs when appropriate

  • Loss of antibody signal upon knockdown of endogenous S1PR1 confirms specificity

• Variable glycosylation: Different expression systems produce varying glycosylation patterns:

  • Characterize glycosylation status by glycosidase treatment

  • Consider enzymatic deglycosylation for applications where homogeneity is critical

  • Select expression systems based on glycosylation requirements

Implementing these solutions helps ensure that studies with recombinant bovine S1PR1 produce reliable, reproducible results that accurately reflect the receptor's native properties and functions.

How can conflicting data on S1PR1 signaling pathways be reconciled in experimental models?

Reconciling conflicting data on S1PR1 signaling often requires careful consideration of experimental contexts. Several strategies can help address apparently contradictory findings:

• Cell type-specific signaling: S1PR1 exhibits distinct signaling patterns across cell types. For example:

  • In endothelial cells, S1PR1 predominantly signals through Gi to enhance barrier function

  • In T cells, S1PR1 signaling drives lymphocyte egress and influences Treg accumulation

  • In cardiomyocytes, S1PR1 interacts with β1-adrenergic receptor in a GRK2-dependent manner

  When comparing studies, carefully note cell types used and consider performing parallel experiments in different cell types relevant to your research question.

• Agonist-specific effects: Different S1PR1 ligands can produce distinct signaling profiles:

  • Natural ligand (S1P) activates multiple downstream pathways

  • Biased agonists (like SAR247799) selectively activate Gi-coupled pathways

  • Functional antagonists (FTY720-P) cause receptor internalization

  Standardize ligand selection across experiments when comparing signaling outcomes.

• Receptor expression levels: Overexpression systems may show different signaling patterns than endogenous systems:

  • High overexpression can lead to constitutive activity

  • Endogenous expression levels preserve normal feedback mechanisms

  • Use inducible expression systems to titrate receptor levels

• Genetic background considerations: Knockout/transgenic models may have compensatory mechanisms:

  • S1PR1 knockout mice show systemic lymphopenia affecting multiple pathways

  • S1PR1-transgenic models may have altered receptor trafficking dynamics

  • Consider using acute interventions (siRNA, CRISPR, pharmacological) alongside genetic models

By systematically addressing these variables, researchers can often reconcile apparently conflicting data and develop a more nuanced understanding of S1PR1 signaling across different physiological and pathological contexts.

What statistical approaches are most appropriate for analyzing S1PR1 functional studies?

Selecting appropriate statistical methods for S1PR1 functional studies depends on the experimental design and data characteristics. Several recommended approaches include:

• For receptor binding studies:

  • Nonlinear regression analysis for saturation binding curves

  • Calculation of Kd, Bmax using one-site or two-site binding models

  • For competition binding, IC50 conversion to Ki using Cheng-Prusoff equation

  • Present binding data as Scatchard plots to identify potential binding site heterogeneity

• For signaling pathway activation:

  • Time-course experiments: Repeated measures ANOVA with appropriate post-hoc tests

  • Dose-response curves: Four-parameter logistic regression to determine EC50 values

  • Western blot quantification: Normalization to loading controls with appropriate paired tests

  • Consider area-under-curve analysis for transient signaling responses

• For functional outcomes in disease models:

  • Animal models (e.g., OIR model): Power analysis to determine appropriate sample sizes

  • For studies comparing WT, knockout, and transgenic animals: One-way ANOVA with post-hoc tests

  • For longitudinal studies: Mixed-effects models to account for repeated measures

• For transendothelial transport experiments:

  • Multiple timepoint measures: Two-way ANOVA with time and treatment as factors

  • Account for potential confounding variables like cell passage number using ANCOVA

  • Use correlation analysis to relate receptor expression levels to transport efficiency